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Abstract
A tumor microenvironment contains various noncancerous cells including adipocytes, 
fibroblasts, immune and inflammatory cells, neuroendocrine cells, pericytes, vascular 
and lymphatic endothelial cells, and the extracellular matrix that surrounds cancerous 
cells. In the tumor microenvironment, cancer cells interact and cross talk with non-
cancerous cells and orchestrate different mechanisms of cancer such as tumorigenesis, 
angiogenesis, and metastasis. Moreover, the expansive nature of cancer cells and chaotic 
angiogenesis affect microcirculation as well as alter the oxygen concentration progres-
sively. Hypoxia, a key player in the multistep process of cancer metastasis, is important 
in different regions of the tumor microenvironment. Hypoxia may transform cancer cells 
to become more aggressive and invasive by triggering overexpression of several hypoxia-
related factors that activate epithelial-mesenchymal transition (EMT). Herein, the current 
knowledge of how hypoxia-driven EMT is presented in the tumor microenvironment of 
solid cancers is discussed.
Keywords: cancer, cancer metastasis, epithelial-mesenchymal transition, hypoxia, 
tumor microenvironment
1. Tumor microenvironment: current perspective
The tumor microenvironment contains a multinetwork of cells, soluble factors, extracellular 
matrix (ECM) components, and signaling molecules that surround and neighbor cancer cells. 
It mediates aberrant tissue function and modulates subsequent progression in solid cancers 
[1]. In this microenvironment, the main structures are the parenchyma, stroma, growth fac-
tors, lymphokines and cytokines, and inflammatory and matrix metalloproteinase enzymes 
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(Figure 1). While cancer cells are located in the parenchyma, noncancerous cells and ECM 
constitute the stroma. Currently, it is known that noncancerous cells have key roles in several 
mechanisms of carcinogenesis, tumor progression, and metastatic cascade [2]. Noncancerous 
cells behave differently in the tumor microenvironment than healthy tissue. However, it is 
still unclear how noncancerous cells and noncellular components of the tumor niche collabo-
rate and assist cancer cells to acquire invasive and metastatic features.
It is known that chronic inflammation is an important factor in shaping the tumor microenvi-
ronment. The major inflammatory cells located in the tumor microenvironment are T lympho-
cytes, natural killer cells, and tumor-associated macrophages (TAMS). TAMs are important in 
ECM destruction/restructuring of the tumor microenvironment, tumor cell motility, and trig-
gering angiogenesis. These cells have both tumor-progressive and tumor-suppressive effects.
In the tumor microenvironment, fibroblasts have various roles under inflammatory condi-
tions. However, they attain new characters and called as “carcinoma-associated fibroblasts” after 
the beginning of the neoplastic process. They constitute 50–70% of the volume of many solid 
epithelial tumors, such as pancreas, stomach, and breast cancers [3]. In addition, they are 
particularly effective in carcinogenesis, tumor progression, and metastasis [4, 5]. Studies on 
carcinoma-associated fibroblasts demonstrated that during the chronic inflammation and 
wound healing, only activated fibroblasts promote tumor growth. There are hypotheses 
about the production of cancer-associated fibroblasts. Genetic changes in normal fibroblast or 
exposure to EMT may directly arise from mesenchymal stem cells [6].
Cancer stem cells (CSCs) are also tumor microenvironment-specific cells. CSCs have been 
intensively researched recently. Today, we know many cancer types consist CSCs in their 
microenvironment, which is associated with aggressive tumor biology and treatment resis-
tance. Moreover, CSCs are responsible for immune modulation during the carcinogenesis [7]. 
Figure 1. A schematic view of the tumor microenvironment.
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In the tumor microenvironment, a unique network has been shown to be created by mainly 
carcinoma-associated fibroblasts and CSCs with the participant of other noncancerous cells. 
This network modulates and regulates different mechanisms of the neoplastic processes, such 
as carcinogenesis, tumor progression, angiogenesis, and metastasis.
Similar to healthy tissue, tumor tissue supplies oxygen and substances from blood and lym-
phatic vessels. Therefore, angiogenesis is a crucial step for tumor growth [8]. However, due 
to the rapid growth of tumor tissue, new blood vessel production is usually insufficient. This 
situation results with decrease of tissue oxygen levels termed as hypoxia. This new condition 
forces cells to acquire new and devastating behaviors such as resistance to environmental 
changes, invasiveness, and also metastatic phenotypes via different mechanisms. In this 
review, we aim to focus on the role of hypoxia and hypoxia-driven EMT in tumor microenvi-
ronment from the current perspective.
2. Hypoxia in tumor microenvironment
Hypoxia is a hallmark of tumor microenvironment. It emerges due to an inadequate blood 
source, which keeps proliferation cells viable. The cellular machinery uses several mecha-
nisms in response to hypoxia. When a decrease in the level of oxygen develops, changes in 
numerous transcriptional regulators are altered.
2.1. Hypoxia: definition
Basically, hypoxia refers to the imbalance between the level of oxygen that the tissues require 
and that can be supplied. It is noteworthy that normoxia describes the “atmospheric” oxygen 
level which is approximately 20–21% (160 mmHg). However, every healthy tissue has lower 
and distinct oxygen levels; therefore, physoxia is a better terminology that defines the normal 
range of oxygen levels in different tissues [9]. The oxygen level of different tissues and can-
cers is presented in Table 1 [10]. Therefore, hypoxic conditions often occur when the oxygen 
Tissue/organ Physoxia (% O
2
) Cancer Hypoxia (% O
2
)
Brain 4.6 Brain tumor 1.7
Breast 8.5 Breast cancer 1.5
Cervix 5.5 Cervix cancer 1.2
Kidney (cortex) 9.5 Renal cancer 1.3
Liver 4.0–7.3 Liver cancer 0.8
Lung 5.6 Lung cancer (nonsmall cancer) 2.2
Pancreas 7.5 Pancreas tumor 0.3
Rectal mucosa 3.9 Rectal cancer 1.8
Table 1. Physoxia and hypoxia of several tissues/organs and cancers.
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tension (pO
2
) decreases lower than 2.5 mmHg, even though tumor oxygen levels are dictated 
by the initial tissue and tumor microenvironment [11, 12]. Moreover, hypoxic regions are 
heterogeneously distributed particularly in the locally advanced tumors [13].
Cancer cells respond to hypoxia in two ways through apoptosis or resistance and survival, 
which is driven by the exposure time. If cancer cells are able to survive, they acquire new 
and unique features. Hypoxic conditions affect the gene transcription, which affords the 
ability of the cancer to survive through invasiveness, genetic instability, and metastasis. 
Furthermore, treatment (radiotherapy and/or chemotherapy) resistance may emerge [14]. A 
hypoxic response is mediated by hypoxia-inducible factors (HIFs), which control many facets 
of cancer cell viability [15].
2.2. Hypoxia-inducible factors
The HIFs orchestrate the responses to hypoxia in normal and cancer cells. Recently, three 
subtypes of HIFs have been introduced: HIF-1, -2, and -3. They are heterodimeric complexes 
and mainly act to mediate cellular processes including angiogenesis, cell proliferation, and 
tissue remodeling in response to hypoxia. HIFs are composed of basic helix-loop-helix-
PER-ARNT-SIM (bHLH-PAS) proteins including an O
2
-labile alpha subunit (HIF-1α, -2α, 
and -3α) and a stable beta subunit (HIF-β). They interact with hypoxia-responsive ele-
ments that contain a conserved RCGTG core sequence [16]. HIF-1α was the first introduced 
prototypic member of HIF family, and has been shown to regulate O
2
-dependent tran-
scriptional responses [17]. After a while from the discovery of HIF-1α, a new HIF protein, 
HIF-2α, was introduced by independent research groups [18–21]. Currently, it is known 
that HIF-1α is the first biomolecule that responds to acute hypoxia, and HIF-2α is the 
major regulator under chronic hypoxic conditions. This phenomenon has been referred as 
the “hypoxic shift” [22]. Holmquist-Mengelbier et al. demonstrated that HIF-1α is active for 
a short duration particularly under hypoxia or anoxia (O
2
 level <0.1%). However, HIF-2α 
is active for a long duration under less severe hypoxia (O
2
 level <5.0%) [23]. Furthermore, 
Pietras et al. reported that the activation of HIF-2α may cause aggressive and infiltrative 
histopathological features under normal oxygen levels, which is termed as “pseudohypoxic 
phenotype” [24–26]. Tian et al. reported a correlation between HIF-2α and vascular endo-
thelial growth factor mRNA expression levels in the endothelium [21]. Therefore, HIF-2α 
overexpression may lead to an increase in chaotic vascularization in the tumor microenvi-
ronment. In 2002, HIF-3 was introduced by Makino et al. [27]. Although the functions of 
HIF-3 are not clear yet, Heikkila et al. indicated that HIF-3 might regulate the activity of 
other HIF complexes [28].
Hypoxic conditions occur heterogenically in almost all types of solid cancers, which lead 
to HIF protein overexpression. Under physiologic conditions, HIF-1α is constitutively 
expressed; however, it is degraded rapidly upon its hydroxylation by prolyl hydroxylases 
(PHDs) [29]. In contrast, the O
2
-dependent PHD inhibition develops under hypoxia and 
HIF-1α protein expression is increased [30]. Under physiological conditions, HIF-1α regu-
lates the expression of important genes that regulate numerous biological processes. In 
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the tumor microenvironment, elevated HIF-α protein expression, which was induced by 
hypoxia or other oncogenic signals, promotes tumor growth, angiogenesis, and prolifera-
tion through the regulation of critical genes (Figure 2). Recent evidence has shown that 
HIF-1α/-2α can impact tumor development through critical oncoproteins and tumor-sup-
pressor genes such as MYC, p53, and mTOR signaling pathway [31–35]. HIFs may also pro-
mote the immune-suppressive mechanisms that promote apoptotic resistance in the tumor 
microenvironment [36]. Therefore, HIF-1α overexpression due to pathological hypoxia 
is generally related to poor prognosis and tumor progression in solid cancer [37, 38]. 
Moreover, HIFs promote the progression of cancer through EMT induction. During the 
EMT, carcinoma cells undergo migration and invasion, leading to cancer progression and 
metastasis [39].
Figure 2. Regulation of HIF in normoxia and hypoxia. During normoxia, PHD enzymes and FIH take role in 
hydroxylation of HIF-α. Hydroxylation of HIF-α by PHDs creates a binding site for the Von Hippel-Lindau (VHL), 
HIF-α-VHL interaction leads to proteasomal degradation. Under hypoxic conditions, PHDs and FIH are inhibited due to 
lack of oxygen. Inhibition of PHDs and FIH lead to HIF-α stabilization and dimerization with its transcriptional partner 
HIF-1β. HIF-α-HIF-1β interaction leads to translocation to the nucleus and binding to consensus hypoxia-responsive 
elements (HRE) within the promoters or enhancers of HIF target genes.
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3. EMT in cancer: an overview
3.1. Epithelial-mesenchymal transition: definition
Epithelial and mesenchymal cells have various functional characteristics. The epithelium is a 
thin layer which consists of the collection of cells with similar features that have been associ-
ated with one to another by cell-to-cell junctions such as tight junctions, adherens junctions, 
desmosomes, and gap junctions. Epithelium layer is polarized because apical side and the 
basal side have different properties that are referred as apicobasal polarity. Of note, cell-to-cell 
junctions consist of cadherins; however, cell-to-basal lamina or ECM junctions consist laminin. 
Moreover, actin is another cell-to-cell adhesion complex which has strong apicobasal polarity. 
All of these junctions provide immobility to the epithelium. On the other hand, mesenchymal 
cells do not have these features and only have focal points that adhere to their neighbor mes-
enchymal cells. Similar to epithelial cells, adhesions between mesenchymal cells can involve 
cadherin for cell-to-cell junctions and integrins for adhesion to ECM. However, they do not 
have junctions for basal lamina. In addition, interstitial collagen and fibronectin are important 
for the ECM adhesion of the mesenchymal cell. They do not have the same ECM molecules 
associated with the apical-basolateral surface (Figure 3).
In 1953, Abercrombie and Heaysman observed that the migration of epithelial cells slows 
down and they realign when contact each other by forming adhesive junctions [40, 41]. 
Conversely, mesenchymal cells, particularly fibroblasts, reorient their direction and move 
away by generating lamellipodia. This process is termed contact inhibition of locomotion. 
Thereafter, they demonstrated that any defect in contact inhibition of locomotion contributes 
to the development of invasive and aggressive characters of cancer cells [42–44]. Today, it is 
known that contact inhibition of locomotion is important in EMT.
EMT is a complex course where epithelial cells are transformed into mesenchymal cells. 
It is coordinated by several different influential factors that lead to behavioral changes 
in epithelial cells. Concisely, epithelial cells lose core properties including the apicobasal 
polarity, cell adhesion, and increase mesenchymal cell properties during the transition 
[45, 46].
Figure 3. A schema for epithelial-mesenchymal transition. Loss of epithelial markers and gain of mesenchymal markers 
during the transition from epithelial phenotype to mesenchymal phenotype.
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EMT is a naturally occurring transdifferentiation process and is critical during embryonic 
development and organogenesis. This phenomenon also occurs during wound healing, tissue 
regeneration, organ fibrosis, and carcinogenesis. In addition, a post-EMT behavior of a part of 
cells may include reverse transition, which is referred as the mesenchymal-epithelial transition [47].
The majority of tumors originate from epithelial tissues of lung, colon, breast, pancreas, pros-
tate, bladder, ovary kidney, liver, and head and neck. Currently, EMT is important in cancer 
progression and metastasis. Epithelial cells may acquire several abilities such as motility, 
invasion, and malignant features via EMT [48]. Moreover, it is known that inflammation is the 
key inducer of EMT in cancer progression. Inflammation may trigger a number of signaling 
pathways involved in carcinogenesis. However, the specific signals that are induced during 
the pathologic EMT in epithelial cancers remain unclear [49].
3.2. EMT in physiology and diseases
The mechanisms under the induction and progression of EMT vary dramatically, even though 
motile cells with mesenchymal phenotype develop consequently. EMT is classified into three 
different subtypes: type-1, -2, and -3. Type-1 EMT (physiologic EMT) is related to implantation, 
embryogenesis, and organ development. It is impacted by remodeling and diversification of 
tissue during morphogenesis. Type-1 EMT is not related with inflammation, fibrosis, and sys-
temic dissemination and generally occurs transiently. Type-2 EMT impacts tissue regeneration 
and fibrosis, and the process depends on continued inflammation in adults. It continues until 
the underlying injuries or infections are resolved/repaired. Type-2 EMT may produce mes-
enchymal cells that are activated. Most notably are the myofibroblasts that produce extreme 
levels of collagen-rich ECM. Type-3 EMT happens in the context of tumor growth/cancer 
progression and the tumors transform to a mesenchymal phenotype. The type-3 EMT induc-
tion is assisted by genomic changes by cancer cells. It may produce cells that have aggressive 
properties, which promote movement into the bloodstream in order to spread to other organs.
3.2.1. Type-1 EMT
Type-1 EMT is the exchange from epithelial cells to mesenchymal cells in the embryonic phase 
events such as implantation, embryogenesis, and organ development. After early embryogenic 
stages, fertilized egg implantation to the endometrium is associated with an EMT [50, 51]. 
This is the first step of type-1 EMT that is accompanied by embryonic morphogenesis. At the 
gastrulation stage, EMT continues with the generation of three germ layers and a primitive 
streak is made in the epiblast layer [52]. The formation of the primitive streak is the most 
important part of gastrulation. Primitive streak leads to three germ layers. Thereafter, all 
tissues are generated during organogenesis by cell migration and differentiation. The EMT 
coordinates almost every stage of this process [53].
At gastrulation level, the EMT is mainly orchestrated by Wnt signaling [54]. Of note, the 
TGF-β superfamily, including Nodal and Vg1, and FGF receptors are in close relation to Wnt 
signaling. Moreover, different signaling modalities through BMPs, c-Myb, and msh homeo-
box 1 (Msx-1) play roles in the regulation of type-1 EMT [55].
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3.2.2. Type-2 EMT
Type-2 EMT is the transition of epithelial cells to mesenchymal cells, which occurs during 
wound healing and fibrosis due to inflammation. It is orchestrated by fibroblasts and inflam-
matory cells, which release multiple inflammatory molecules, signals, and ECM components 
such as collagens, laminins, elastin, tenascin, and other matrix molecules. A variety of studies 
demonstrated an association between EMT and progressive organ fibrosis such as kidney and 
lung disease [56, 57].
Inflammatory cells and fibroblasts produce proteins such as FSP1, S100 cytoskeletal proteins, 
α-SMA, and collagen I that develop during the development of organ fibrosis [57]. These 
proteins have been used as a biomarker for fibrosis of organs, which are undergoing an EMT 
associated with chronic inflammation. However, epithelial markers, including cytokeratin 
and E-cadherin, continue to be expressed until they gain a complete fibroblastic phenotype 
[58]. Rastaldi et al. evaluated the EMT in human renal biopsies of 133 patients with kidney 
fibrosis. The EMT was detected in the fibrotic kidney based on the staining for cytokeratin, 
vimentin, α-SMA, and zona occludens 1 (ZO-1) [59]. Kidney fibrosis has been associated with 
multiple inflammatory cells that induce EMT with various growth factors such as TGF-β, 
EGF, and FGF-2 [60]. As the role of TGF-β has been determined in kidney fibrosis, several 
researchers focused on the inhibition of TGF-β using BMP-7 [61]. Morrissey et al. demon-
strated that BMP-7 provided the reversal of EMT and repaired tubular structural damage and 
repopulation of healthy tubular epithelial cells of mice with kidney fibrosis [62].
3.2.3. Type-3 EMT
Type-3 EMT is the transmission of epithelial cells to mesenchymal cells in cancer progression, 
also known as the “oncogenic epithelial-mesenchymal transition.” Due to its complexity, onco-
genic EMT is more complex than physiologic EMT. The role of type-3 EMT has been demon-
strated in different cancer cells. For example, breast and prostate cancer cells can be classified 
as epithelial predominated or mesenchymal predominated [63, 64]. Zajchowski et al. studied 
different molecules to predict invasiveness of breast cancer by using gene array method and 
showed that epithelial proteins are related to noninvasiveness, whereas mesenchymal pro-
teins are related to invasiveness [65]. Currently, several in vitro/in vivo studies demonstrated 
that mesenchymal status leads to an invasive phenotype, motility, and metastasis in cancers.
In solid tumors, loss of E-cadherin [66], cadherin transformation [67], adhesion loss, changes 
in apicobasal polarity, and tissue architecture modifications have been demonstrated in 
EMT. In addition, vimentin, N-cadherin, fibronectin, that are the mesenchymal markers, are 
highly expressed during the EMT [48]. In carcinogenesis and tumor progression, the loss 
of E-cadherin and increase in the N-cadherin, which is referred as “cadherin switch,” are the 
most significant indicators of the EMT. Currently, it is known that cadherin switch breaks 
down cell-to-cell junctions and controls the contact inhibition of locomotion. Moreover, it 
may modulate signal transduction in metastatic cascade [68]. The association between tumor 
progression and cadherin switch has been demonstrated in prostate cancer, urothelial blad-
der carcinoma, and malignant melanoma [67, 69, 70].
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In literature, there are evidences that support the idea of “high levels of mesenchymal mark-
ers are often related to aggressive tumor behavior and poor prognosis.” In cervix cancers, the cor-
relation between lymph node metastasis and vimentin positivity was also determined [71]. 
Nevertheless, this correlation has been reported in a small number of cancer types. Therefore, 
it is hard to mention that vimentin is a definitive predictor of aggressiveness for all cancer 
types. Ahmad et al. suggested another biomarker for metastatic breast cancer: stromelysin-3. 
Stromelysin-3 is a matrix metalloproteinase and marker for mesenchymal cells. Breast carci-
noma cells that undergo EMT are able to express stromelysin-3, which may partly explain the 
increased metastatic propensity detected in these tumors [72].
Recently, the genetic and biochemical properties that underlie acquirement of cancer cell 
invasiveness and metastasis are the major areas of intensive research. Xue and colleagues 
demonstrated that cancer cells departing HER-2/neu expressed a GFP transgene that was 
facilitated by FSP-1. Moreover, the low rate of metastasis was detected in FSP-1 null mice 
[73]. This research provided important evidences for the mechanism of metastasis related to 
EMT. In addition, Yang et al. reported that tumor cells were able to behave like mesenchy-
mal cells and express mesenchymal markers [74]. Besides the evidences about EMT in the 
metastatic process, some studies have also shown data on reverse EMT. They suggest that the 
reversibility of EMT is observed during embryonic development and also during the tumor 
growth at metastatic side. Tumor cells try to undergo not only growth but also cell differen-
tiation to resemble the originating epithelium. Brabletz et al. demonstrated the similarity of 
epithelial nature between primary tumor side and metastatic tissue for colorectal cancers [75]. 
It indicates that the induction of an EMT is likely to be central and crucial for the metastatic 
cascade and implicates EMT during the colonization process.
3.3. Molecular mechanisms and pathways of EMT
In pathologic or physiologic events, the EMT is triggered and controlled by different signaling 
pathways. Several transcription factors have been described for the regulation of EMT. Tumor 
growth factor-β signaling appears to be one of the most important pathways. It generally acts 
as an epithelial cell proliferation suppressor. However, it may also positively affect the tumor 
progression and metastasis [76, 77]. TGF-β can induce the EMT via two signaling pathways. 
The first pathway involves Smad proteins that regulate the action of tumor growth factor-β 
by affecting ALK-5 receptors. Smad proteins mediate signaling pathway effects on motility of 
cells [61, 78]. Inhibitory Smad can induce autocrine production of TGF-β, thereby, reinforcing 
epithelial-mesenchymal transition [79]. Recently, β-catenin and LEF found to be relevant with 
Smad in PDGF-induced EMT [80]. Currently, it is known that TGF-β/Smad/LEF/PDGF axis 
has important effects on EMT during cancer progression. The second mechanism for TGF-β-
induced EMT is MAPK-dependent pathway [81].
Several studies have demonstrated the association between reduced cancer cell E-cadherin 
levels and activation of EMT [82, 83]. Eger et al. showed that the cFos oncogene induction 
in mouse mammary epithelial cells induced the EMT by decreasing E-cadherin [84]. The 
movement of β-catenin from the cytoplasm to nucleus causes acquisition of mesenchymal 
phenotype by affecting E-cadherin expression. Nuclear buildup of β-catenin has been shown 
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to reduce E-cadherin expression and acquisition of invasive phenotype [85]. Scarpa et al. 
described the E-cadherin loss as an activation and contact-dependent cell polarity process 
via Rac signaling [86]. Currently, it is known that reduced E-cadherin levels are highly cor-
related with poor prognosis and decrease in survival in various cancers such as hepatocellular 
carcinoma, nonsmall cell lung, oral, esophageal, gastric, cervix and breast cancer, and bone 
and soft tissue sarcoma [87–95].
3.4. EMT in cancer metastasis: guilty or innocent?
Cancer metastasis is a complex multistep process with sequential molecular and cellular 
events that promote the transformation of cells, intravasation, survival and ultimately extrav-
asation, implantation, growth, and colonization in a new and foreign tissue environment. As 
mentioned above, several evidences support that EMT has a major role in cancer metastasis. 
The EMT signifies the first step of the metastatic cascade. During EMT, cancer cells are able to 
invade adjacent cell layers following the loss of cell-to-cell adhesion and acquiring motility. 
Principally, the result of cellular motility is similar to the extensive cell migration and tissue 
reorganization that occurs during the embryogenesis and organogenesis; however, subse-
quent steps have different and complex events.
After a journey in the bloodstream, cancer cells that can escape from the immune system, 
extravasate from the circulation in order to implant and proliferate at the target organ, “seed 
and soil theory.” Thereby, a colony of the primary tumor can regrow by inducing angiogenesis 
in a foreign and apparently “hostile” background. This process is induced by not only genetic/
epigenetic factors but also by the nonneoplastic stromal cells [96]. In vivo studies demonstrated 
that this development is generally supplemented with partial or complete EMT. Therefore, 
the induction of EMT results in the acquisition of metastatic properties in different carcinoma 
cell lines. Main indicators for the acquisition of mesenchymal properties are the high level 
of mesenchyme-specific proteins [46]. In contrast to many studies, Tarin et al. reported that 
the acquirement of mesenchymal markers during tumor progression reflects genomic insta-
bility. Therefore, they advocated that EMT does not occur in carcinogenesis [97]. However, 
synchronized and complex gene-expression patterns are required to provide tumor cells with 
the mesenchymal properties. Moreover, genomic instability may have more important role in 
the regulation of EMT. For instance, SNAI1 regulates expression of EMT-associated genes in 
colorectal carcinoma [98].
A significant evidence for EMT during the metastatic process was presented by Yang et al. 
They reported that cancer cells were able to behave like mesenchymal cells and express 
α-SMA, FSP1, desmin, and vimentin [74]. Studies that include functional manipulations on 
EMT process also provide evidences. For instance, depletion of FSP1/S100A4-positive cells in 
tumors suppresses metastasis [73].
In adenomatous polyposis coli (APC) and β-catenin mutation-positive colorectal cancers, 
β-catenin levels are predominantly observed in tumor cells localized at invasion. Moreover, 
tumor cells with nuclear β-catenin seem to have undergone EMT [99]. Regardless of numer-
ous studies, the major problem for the demonstration of the role of EMT in the metastatic 
cascade is the detection of cancer cells that have undergone EMT in primary human tumors. 
Cancer Metastasis16
The markers of EMT indicate epithelial phenotype or mesenchymal phenotype not the EMT 
in cancer metastasis. Therefore, in vivo studies with more sensitive indicators are required for 
understanding the role of EMT in cancer metastasis.
4. A new insight into the mechanisms of hypoxia-induced EMT
Hypoxia is a common situation in tumor microenvironment affecting cancer cell behavior, 
including progression and metastasis. Currently, it is clearly known that exposure to hypoxic 
conditions results in HIF-1α overexpression. As mentioned previously, overexpression 
of HIF-1a is related with promoting EMT for cancer cells. Additionally, it has been dem-
onstrated that hypoxia-induced EMT includes the loss of cell adhesion and cell polarity. It 
has been observed that hypoxic conditions decrease the E-cadherin expression, but increase 
N-cadherin expression, a mesenchymal marker [100].
Azab et al. previously demonstrated that multiple myeloma cancer cells cultured in hypoxic 
conditions and injected into mice were able to spread to the new bone marrow faster than the 
cells cultured under normoxic conditions [101]. The hypoxia-induced EMT is mainly driven 
by stabilization and activation of HIF1α. It is controlled by epigenetic changes that result in 
a loss of tumor-suppressor functions and gain of oncogene functions (Ras, Raf, Src, mTOR, 
and Myc). Besides hypoxic conditions, the HIF pathway is also regulated by hypoxia-inde-
pendent manner [102, 103]. Hypoxia-independent HIF-α stabilization and activation happens 
in response to cytokines, lipopolysaccharide (LPS), and growth factors in EMT mediated by 
PI3K/AKT/mTOR,29,30 MAPK,41 and NFĸB pathways [104–106].
HIF-1α regulates hundreds of genes, and not only controls malignant and metastatic cancer 
cells but is also resistant to treatments. Thus, inhibition of hypoxia-induced EMT or HIF-1α 
may be promising as an anticancer therapy. Currently, there are many researches ongoing in 
this field. Besides targeting HIF-1α, another strategy is to block metastasis and target genes 
downstream of HIF-1α. Kaneko et al. have researched the hypoxia-induced EMT in oral cav-
ity squamous cell carcinoma and showed that hypoxia-induced EMT in oral cavity cancer was 
improved by GSK3-β phosphorylation via PI3 K/Akt signaling [107]. Jiao and Nan showed 
that hypoxia-induced EMT and chemoresistance were supplemented with HIF-1α expres-
sion and Akt activation. Moreover, they demonstrated that PI3K/Akt and HIF-1α inhibition 
improved the therapeutic efficacy of hypoxic chemotherapy [108]. Lo Dico et al. reported 
that miR-675-5p promotes glioma growth through HIF-1α stabilization. Subsequently, they 
examined miR-675-5p specifically in colon cancer metastasis and demonstrated overexpres-
sion contributes to tumor progression through HIF-1α-induced EMT [109, 110].
5. Conclusion
Hypoxia is a hallmark of cells in the tumor microenvironment and has a major role in the 
carcinogenesis and metastasis processes. Hypoxia controls many crucial events such as tumor 
neovascularization, metabolism, cell survival, and cell death. Furthermore, hypoxia causes 
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EMT and CSC-like properties including resistance to treatment. Each step of the cancer adap-
tive process is regulated by HIF, NFĸB, PI3K, and MAPK pathways. Understanding the impact 
of hypoxia and clarifying the hypoxia-induced responses and signaling modalities may pave 
the way to achieve important steps against cancer via hypoxia/HIF-targeted treatments.
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